Predictors of mammographic density among women with a strong family history of breast cancer

Abstract Background Mammographic density is one of the strongest risk factors for breast cancer. In the general population, mammographic density can be modified by various exposures; whether this is true for women a strong family history is not known. Thus, we evaluated the association between reproductive, hormonal, and lifestyle risk factors and mammographic density among women with a strong family history of breast cancer but no BRCA1 or BRCA2 mutation. Methods We included 97 premenopausal and 59 postmenopausal women (age range: 27-68 years). Risk factor data was extracted from the research questionnaire closest in time to the mammogram performed nearest to enrollment. The Cumulus software was used to measure percent density, dense area, and non-dense area for each mammogram. Multivariate generalized linear models were used to evaluate the relationships between breast cancer risk factors and measures of mammographic density, adjusting for relevant covariates. Results Among premenopausal women, those who had two live births had a mean percent density of 28.8% vs. 41.6% among women who had one live birth (P=0.04). Women with a high body weight had a lower mean percent density compared to women with a low body weight among premenopausal (17.6% vs. 33.2%; P=0.0006) and postmenopausal women (8.7% vs. 14.7%; P=0.04). Among premenopausal women, those who smoked for 14 years or longer had a lower mean dense area compared to women who smoked for a shorter duration (25.3cm2 vs. 53.1cm2; P=0.002). Among postmenopausal women, former smokers had a higher mean percent density (19.5% vs. 10.8%; P=0.003) and dense area (26.9% vs. 16.4%; P=0.01) compared to never smokers. After applying the Bonferroni correction, the association between body weight and percent density among premenopausal women remained statistically significant. Conclusions In this cohort of women with a strong family history of breast cancer, body weight was associated with mammographic density. These findings suggest that mammographic density may explain the underlying relationship between some of these risk factors and breast cancer risk, and lend support for the inclusion of mammographic density into risk prediction models.

Download Full-text

Abstract P4-10-08: Family history of breast cancer and mammographic density in premenopausal women

10.1158/1538-7445.sabcs18-p4-10-08 ◽

2019 ◽

Author(s):

Y Han ◽

X Zong ◽

GA Colditz ◽

AT Toriola

Keyword(s):

Breast Cancer ◽

Family History ◽

Mammographic Density ◽

Premenopausal Women ◽

History Of

Download Full-text

Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer

Cancer ◽

10.1002/1097-0142(19910915)68:6<1401::aid-cncr2820680637>3.0.co;2-k ◽

1991 ◽

Vol 68 (6) ◽

pp. 1401-1405 ◽

Cited By ~ 32

Author(s):

Richard R. Love ◽

David R. Rose ◽

Tanya S. Surawicz ◽

Polly A. Newcomb

Keyword(s):

Breast Cancer ◽

Growth Hormone ◽

Family History ◽

Premenopausal Women ◽

Strong Family History ◽

Hormone Levels ◽

Healthy Women ◽

History Of

Download Full-text

Re: Risk Factors for Breast Cancer According to Family History of Breast Cancer

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/88.14.1003 ◽

1996 ◽

Vol 88 (14) ◽

pp. 1003-1004 ◽

Cited By ~ 3

Author(s):

F. PARAZZINI ◽

C. L. VECCHIA ◽

L. CHATENOUD ◽

E. NEGRI ◽

S. FRANCESCHI

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Family History ◽

History Of

Download Full-text

Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer

JNCI Cancer Spectrum ◽

10.1093/jncics/pky071 ◽

2018 ◽

Vol 2 (4) ◽

Cited By ~ 6

Author(s):

Louise Eriksson ◽

Wei He ◽

Mikael Eriksson ◽

Keith Humphreys ◽

Jonas Bergh ◽

...

Keyword(s):

Breast Cancer ◽

Mammographic Density ◽

Adjuvant Treatment ◽

Premenopausal Women ◽

Cancer Registries ◽

Dense Area ◽

Intention To Treat ◽

Density Reduction ◽

Treatment Information ◽

Drug Register

Abstract Background Tamoxifen decreases mammographic density. Whether compliance affects this relationship is unclear as is the relationship between other types of adjuvant treatment and changes in mammographic density. Methods This prospective cohort study included 2490 women diagnosed with breast cancer during 2001–2015 in Sweden. Mammographic density was assessed within 3 months of diagnosis and 6–36 months post diagnosis. Logistic regression was performed to study the association between each respective adjuvant treatment and mammographic density reduction (annual dense area decrease >15%). Results Intention-to-treat analyses using treatment information from the regional cancer registries showed that tamoxifen-treated patients more frequently experienced mammographic density reductions compared with nontreated patients (odds ratio [OR] = 1.58, 95% confidence interval [CI] = 1.25 to 1.99), as did chemotherapy-treated patients (OR = 1.28, 95% CI = 1.06 to 1.54). For chemotherapy, the association was mainly seen in premenopausal women. Neither aromatase inhibitors nor radiotherapy was associated with density change. Tamoxifen use based on prescription and dispensation data from the Swedish Prescribed Drug Register showed that users were more likely to have density reductions compared with nonusers (adjusted OR = 2.24, 95% CI = 1.40 to 3.59). Moreover, among tamoxifen users, tamoxifen continuers were more likely than discontinuers to experience density reductions (adjusted OR = 1.50, 95% CI = 1.04 to 2.17). Conclusions Our results indicate that adherence influences the association between tamoxifen and mammographic density reduction. We further found that chemotherapy was associated with density reductions and propose that this is largely secondary to chemotherapy-induced ovarian failure.

Download Full-text

A retrospective study on breast cancer presentation, risk factors, and protective factors in patients with a positive family history of breast cancer

The Breast Journal ◽

10.1111/tbj.13520 ◽

2020 ◽

Vol 26 (3) ◽

pp. 469-473

Author(s):

Ying Yi Liaw ◽

Foong Shiang Loong ◽

Suzanne Tan ◽

Sze Yun On ◽

Evelyn Khaw ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Retrospective Study ◽

Family History ◽

Protective Factors ◽

Positive Family History ◽

History Of

Download Full-text

Risk Factors of Breast Cancer in Relation to a Family History of Breast Cancer in Southern Sweden1

Familial Cancer ◽

10.1159/000412524 ◽

2015 ◽

pp. 34-35 ◽

Cited By ~ 1

Author(s):

H. Olsson ◽

M. Landin Olsson ◽

U. Kristoffersson ◽

J. Ranstam

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Family History ◽

History Of

Download Full-text

Hospital visitors as controls in case-control studies

Revista de Saúde Pública ◽

10.1590/s0034-89102001000500005 ◽

2001 ◽

Vol 35 (5) ◽

pp. 436-442 ◽

Cited By ~ 5

Author(s):

Gulnar Azevedo S Mendonça ◽

José Eluf-Neto

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Family History ◽

Case Control ◽

Breast Size ◽

Case Control Studies ◽

Family History Of Cancer ◽

History Of ◽

Incident Cases ◽

History Of Cancer

OBJECTIVE: Selecting controls is one of the most difficult tasks in the design of case-control studies. Hospital controls may be inadequate and random controls drawn from the base population may be unavailable. The aim was to assess the use of hospital visitors as controls in a case-control study on the association of organochlorinated compounds and other risk factors for breast cancer conducted in the main hospital of the "Instituto Nacional de Câncer" -- INCA (National Cancer Institute) in Rio de Janeiro (Brazil). METHODS: The study included 177 incident cases and 377 controls recruited among female visitors. Three different models of control group composition were compared: Model 1, with all selected visitors; Model 2, excluding women visiting relatives with breast cancer; and Model 3, excluding all women visiting relatives with any type of cancer. Odds ratios (OR) and 95% confidence intervals were calculated to test the associations. RESULTS: Age-adjusted OR for breast cancer associated with risk factors other than family history of cancer, except smoking and breast size, were similar in the three models. Regarding family history of all cancers, except for breast cancer, there was a decreased risk in Models 1 and 2, while in Model 3 there was an increased risk, but not statistically significant. Family history of breast cancer was a risk factor in Models 2 and 3, but no association was found in Model 1. In multivariate analysis a significant risk of breast cancer was found when there was a family history of breast cancer in Models 2 and 3 but not in Model 1. CONCLUSIONS: These results indicate that while investigating risk factors unrelated to family history of cancer, the use of hospital visitors as controls may be a valid and feasible alternative.

Download Full-text

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

Breast Cancer Research ◽

10.1186/s13058-020-01349-9 ◽

2020 ◽

Vol 22 (1) ◽

Cited By ~ 1

Author(s):

Joyce O’Shaughnessy ◽

Christine Brezden-Masley ◽

Marina Cazzaniga ◽

Tapashi Dalvi ◽

Graham Walker ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Ovarian Cancer ◽

Risk Factor ◽

Metastatic Breast Cancer ◽

Family History ◽

Metastatic Breast ◽

Cytotoxic Chemotherapy ◽

First Line ◽

History Of

Abstract Background The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Methods Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negative MBC within 90 days prior to enrollment. Hormone receptor (HR)-positive patients had experienced disease progression on or after prior endocrine therapy, or endocrine therapy was considered unsuitable. gBRCAm status was determined using baseline blood samples or prior germline test results. For patients with a negative gBRCAm test, archival tissue was tested for somatic BRCAm and homologous recombination repair mutations (HRRm). Details of first-line cytotoxic chemotherapy were also collected. Results Between March 2017 and April 2018, 384 patients from 14 countries were screened and consented to study enrollment; 341 patients were included in the full analysis set (median [range] age at enrollment: 56 [25–89] years; 256 (75.3%) postmenopausal). Overall, 33 patients (9.7%) had a gBRCAm (16 [4.7%] in gBRCA1 only, 12 [3.5%] in gBRCA2 only, and 5 [1.5%] in both gBRCA1 and gBRCA2). gBRCAm prevalence was similar in HR-positive and HR-negative patients. gBRCAm prevalence was 9.0% in European patients and 10.6% in Asian patients and was higher in patients aged ≤ 50 years at initial breast cancer (BC) diagnosis (12.9%) than patients aged > 50 years (5.4%). In patients with any risk factor for having a gBRCAm (family history of BC and/or ovarian cancer, aged ≤ 50 years at initial BC diagnosis, or triple-negative BC), prevalence was 10.4%, versus 5.8% in patients without these risk factors. HRRm prevalence was 14.1% (n = 9/64) in patients with germline BRCA wildtype. Conclusions Patient demographic and disease characteristics supported the association of a gBRCAm with younger age at initial BC diagnosis and family history of BC and/or ovarian cancer. gBRCAm prevalence in this cohort, not selected on the basis of risk factors for gBRCAm, was slightly higher than previous results suggested. gBRCAm prevalence among patients without a traditional risk factor for harboring a gBRCAm (5.8%) supports current guideline recommendations of routine gBRCAm testing in HER2-negative MBC, as these patients may benefit from poly(ADP-ribose) polymerase (PARP) inhibitor therapy. Trial registration NCT03078036.

Download Full-text

Assessment of Breast Cancer Risk Based on Mammary Gland Volume Measured with CT

Breast Cancer Basic and Clinical Research ◽

10.4137/bcbcr.s5248 ◽

2010 ◽

Vol 4 ◽

pp. BCBCR.S5248 ◽

Cited By ~ 3

Author(s):

Megumi Kuchiki ◽

Takaaki Hosoya ◽

Akira Fukao

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Cancer Patients ◽

Odds Ratio ◽

Premenopausal Women ◽

Breast Cancer Patients ◽

History Of ◽

The Relationship

We investigated the relationship between mammary gland volume (MGV) of the breast as measured with three-dimensional chest computed tomography (CT) and breast cancer risk. Univariate analysis was used to assess the relationship between MGV and known risk factors in 427 healthy women. A case control study (97 cases and 194 controls) was conducted to assess breast cancer risk. MGV was significantly smaller for postmenopausal women than for premenopausal women, and was significantly larger for women with a family history of breast cancer than for women without. MGV, body mass index (BMI), and rate of family history of breast cancer were significantly higher among breast cancer patients than among healthy women, and number of deliveries was significantly lower among breast cancer patients. In postmenopausal women, age at menarche was significantly younger for breast cancer patients. MGV correlated well with breast cancer risk factors. The highest odds ratio was 4.9 for premenopausal women with the largest MGV. Regardless of menopausal status, the greater the MGV, the higher the odds ratio. Our results constitute the first reliable data on the relationship between MGV and breast cancer obtained through exact volume analysis.

Download Full-text